A randomized, parallel, open-label clinical study comparing the effectiveness and safety of apremilast with methotrexate in individuals with moderate to severe palm plantar psoriasis.

Abstract

Various studies have revealed varying outcomes regarding the safety and effectiveness of
apremilast in comparison to methotrexate. Therefore, more research into the function of A
premilast in palmo plantar psoriasis is required. Patients with moderate to severe palmoplantar
psoriasis were the subjects of a randomized, prospective, parallel-group, open-label trial. For 16
weeks, they were randomly assigned to either the methotrexate group (n = 19) or the apremilast
group (n = 22). Reduced scores on the modified palmoplantar psoriasis severity index
(mPPPASI) from week 0 to week 16 served as the primary effectiveness metric. Additional
metrics included the percentage of patients who achieved a Static Physician Global Assessment
score of 0 (clear) or 1 (almost clear), the percentage of patients who achieved mPPPASI75 (75%
reduction in mPPPASI score) by the end of 16 weeks, and the proportion of patients who
demonstrated a dermatology life quality index decline of at least 5àpoints from the beginning. At
16 weeks, there was no statistically significant difference between the two groups in terms of m-
PPPASI score drop, however there was a significant decline from week 0 to week 16 within the
group. The secondary efficacy measures had identical outcomes. Out of the twenty-four adverse
events documented in the methotrexate group, three individuals had abnormal liver function
tests. Out of the 19 adverse events documented in the apremilast group, 2 patients had an
infection of the upper respiratory tract. In the treatment of moderate to severe palmoplantar
psoriasis, apremilast is just as effective as methotrexate, but it is more tolerable. Static Physician
Global Assessment, Dermatology Life Quality Index, Palmoplantar Psoriasis, Palmoplantar
Psoriasis Area and Severity Index, Apremilast